New Implantable Cell-Therapy Platform Moves Toward First Human Testing in Type 1 Diabetes

For decades, researchers have explored whether transplanting insulin-producing cells could restore blood sugar control in Type 1 diabetes. One major obstacle: the immune system attacks these transplanted cells, and protecting them typically requires strong drugs that affect the whole body. Continuity Biosciences and Breakthrough T1D are now testing a technology designed to work around this problem.

NICHE is an implantable device that stays in the body but can be removed if needed. Inside, it combines insulin-producing cells with a separate chamber containing medicines. The key innovation is delivering immune-protection drugs locally—directly to where the transplanted cells live—rather than flooding the entire body with immunosuppressive medications.

Islet transplantation has long faced two critical challenges. First, transplanted cells need a blood supply to survive and function. Second, the body's immune system must be prevented from destroying them. Current approaches often rely on heavy systemic immunosuppression, which carries significant side effects.

NICHE addresses both issues simultaneously. The device includes a prevascularized chamber—designed to promote the growth of blood vessels around the transplanted cells. At the same time, the integrated drug reservoir delivers immune-protecting agents directly to the graft's microenvironment, potentially requiring lower doses of systemic immunosuppressive drugs.

The collaboration between Continuity and Breakthrough T1D, funded through Breakthrough T1D's Industry Discovery and Development Partnership program, will support the preparation work needed before testing in humans. This includes IND-enabling development—the preclinical studies and manufacturing processes required by regulators before a first-in-human trial can begin.

If these steps proceed as planned, a Phase 1/2a clinical trial could begin testing NICHE in people living with Type 1 diabetes. Phase 1/2a studies typically focus on safety and early signs of effectiveness in a small group of participants, establishing whether the approach warrants larger-scale investigation.

Cell-based therapies for Type 1 diabetes remain experimental, and successful transplantation has been achieved mainly in specialized centers with experienced teams. NICHE represents one of several emerging technologies aimed at making cell therapy more practical and accessible by reducing the burden of systemic immunosuppression.

The device's retrievability—meaning it can be removed—is also notable, as it may offer a safety advantage over permanent implants. However, much remains to be learned. The planned human trial will be the first opportunity to test whether this promising laboratory approach translates to real-world benefit.

Origin: prnewswire.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.